Arena Pharma licenses temanogrel to Ildong Pharma for South Korea
The USA’s Arena Pharmaceuticals (Nasdaq: ARNA) has entered into a co-development and license agreement with South Korea’s Ildong Pharmaceutical for temanogrel, Arena's internally discovered inverse agonist of the serotonin 2A receptor.
This is the second deal this month between the two companies The Pharma Letter November 8). Arena entered into a marketing and supply agreement with Ildong for its weight loss drug Belviq (lorcaserin HCl), granting it exclusive rights to market and distribute the product in South Korea for weight loss or weight management in obese and overweight patients, subject to regulatory approval of Belviq by the Korea Food and Drug Administration (KFDA).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze